Unipharm, one of Israel’s leading generic pharmaceutical companies, has undergone significant growth in recent years. Their new, EU-GMP certified manufacturing facility, which opened in 2017, offers the latest technology in oral solid and oral solution development and production. Their generic portfolio spans a wide range of therapeutic areas, including unique niche opportunities.
Unipharm has made a name for itself through its involvement in shaping and developing intellectual property laws in Israel and worldwide. The company’s legal achievements in pharmaceutical patent cases have led to a consistent track record of successful and early generic launches.
Unipharm’s generics are offered for out-licensing to all international markets. Its EU CTD dossiers are available along with full regulatory support to achieve successful and swift marketing approvals.
Unipharm is currently seeking partners/distributors in Ghana.
For more information on Unipharm and interest in supplying its 2022 product portfolio, please contact Mr. Edwin Acquah, our lead on Pharmaceuticals and Healthcare.